Floatz logo

Encorafenib

BRAF V600E

Dr. Ronnie ShapiraSmall moleculePhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the BRAF V600E cohort.

Asset / SponsorPhaseRating
Calcium folinate pentahydrate
Institut de Recherches Internationales Servier
Phase 2BB
FLUOROURACILUM
Institut de Recherches Internationales Servier
Phase 2BB
Irinotecan
Institut de Recherches Internationales Servier
Phase 2BB
Cetuximab
Tianjin Medical University Cancer Institute and Hospital
Phase 2B
Binimetinib
Dr. Ronnie Shapira
Phase 2B

View all 13 →

Same molecule, other indications

Encorafenib is also rated in:

colon carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
colon adenocarcinomaDormant
BB
Indicative ·
67 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →